Your browser doesn't support javascript.
loading
Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
Gru, Alejandro A; Lim, Megan S; Dogan, Ahmet; Horwitz, Steven M; Delabie, Jan; Fu, Kai; Peker, Deniz; Reddy, Vishnu V B; Xu, Mina L; Vij, Kiran; Slack, Graham W; Miranda, Roberto N; Jagadeesh, Deepa; Lisano, Julie M; Hsi, Eric D; Torlakovic, Emina.
Afiliação
  • Gru AA; From the Department of Pathology, E. Couric Clinical Cancer Center, University of Virginia, Charlottesville (Gru).
  • Lim MS; The Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia (Lim).
  • Dogan A; The Department of Pathology and Laboratory Medicine (Dogan), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Horwitz SM; The Department of Medical Oncology (Horwitz), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Delabie J; The Department of Laboratory Medicine & Pathobiology, University Health Network, Toronto, Ontario, Canada (Delabie).
  • Fu K; The Department of Pathology, Roswell Park Cancer Institution, Buffalo, New York (Fu).
  • Peker D; The Department of Pathology & Laboratory Medicine, Emory University, Atlanta, Georgia (Peker).
  • Reddy VVB; The Department of Pathology, University of Alabama Medical Center, Birmingham (Reddy).
  • Xu ML; The Department of Pathology, Yale School of Medicine, Yale University, New Haven, Connecticut (Xu).
  • Vij K; The Departments of Internal Medicine and Pathology & Immunology, Washington University School of Medicine, St Louis, Missouri (Vij).
  • Slack GW; The Department of Pathology and Laboratory Medicine, British Columbia Cancer, Vancouver, British Columbia, Canada (Slack).
  • Miranda RN; The Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston (Miranda).
  • Jagadeesh D; The Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio (Jagadeesh).
  • Lisano JM; Medical Affairs, Seagen Inc, Bothell, Washington (Lisano).
  • Hsi ED; The Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina (Hsi).
  • Torlakovic E; The Department of Pathology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada (Torlakovic).
Arch Pathol Lab Med ; 147(1): 79-86, 2023 01 01.
Article em En | MEDLINE | ID: mdl-35472771
CONTEXT.­: Although CD30 testing is an established tool in the diagnostic workup of lymphomas, it is also emerging as a predictive biomarker that informs treatment. The current definition of CD30 positivity by immunohistochemistry is descriptive and based on reactivity in lymphomas that are defined by their universal strong expression of CD30, rather than any established threshold. Challenges include inconsistencies with preanalytic variables, tissue processing, pathologist readout, and with the pathologist and oncologist interpretation of reported results. OBJECTIVE.­: To develop and propose general best practice recommendations for reporting CD30 expression by immunohistochemistry in lymphoma biopsies to harmonize practices across institutions and facilitate assessment of its significance in clinical decision-making. DESIGN.­: Following literature review and group discussion, the panel of 14 academic hematopathologists and 2 clinical/academic hematologists/oncologists divided into 3 working groups. Each working group was tasked with assessing CD30 testing by immunohistochemistry, CD30 expression readout, or CD30 expression interpretation. RESULTS.­: Panel recommendations were reviewed and discussed. An online survey was conducted to confirm the consensus recommendations. CONCLUSIONS.­: CD30 immunohistochemistry is required for all patients in whom classic Hodgkin lymphoma and any lymphoma within the spectrum of peripheral T-cell lymphoma are differential diagnostic considerations. The panel reinforced and summarized that immunohistochemistry is the preferred methodology and any degree of CD30 expression should be reported. For diagnostic purposes, the interpretation of CD30 expression should follow published guidelines. To inform therapeutic decisions, report estimated percent positive expression in tumor cells (or total cells where applicable) and record descriptively if nontumor cells are positive.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma de Células T Periférico Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfoma de Células T Periférico Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article